{
    "clinical_study": {
        "@rank": "70535", 
        "acronym": "VAULT", 
        "arm_group": {
            "arm_group_label": "aflibercept", 
            "arm_group_type": "Experimental", 
            "description": "Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year)."
        }, 
        "brief_summary": {
            "textblock": "Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy\n      (PCV) will be evaluated."
        }, 
        "brief_title": "Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Exudative Age-related Macular Degeneration", 
            "Polypoidal Choroidal Vasculopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "detailed_description": {
            "textblock": "Efficacy of VEGF Trap-Eye (aflibercept, Eylea) for exudative age-related macular\n      degeneration (AMD) was demonstrated in the phase III VIEW study. Polypoidal choroidal\n      vasculopathy (PCV) is considered as a subtype of exudative AMD, however it is reportedly\n      different from choroidal new vessels based on the histologic studies. The aim of this study\n      is to evaluate effects of VEGF Trap-Eye in treatment of PCV, which was diagnosed using\n      indocyanine green (ICG) angiography. VEGF Trap-Eye will be injected intravitreally bimonthly\n      after 3 monthly loading dose for 12 months in treatment-naive PCV patients. The efficacy\n      will be evaluated on preserving visual acuity and improving angiographic features at 12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Submacular PCV diagnosed using ICG angiography with no previous treatment (branching\n             vascular network with or without polypoidal dilation in ICG angiography)\n\n          -  Presence of signs of recent activity of PCV\n\n               1. Visual acuity between 20/40 and 20/320\n\n               2. Active leakage in fluorescein angiography\n\n               3. Presence of any fluid in OCT(optical coherence tomography)-intraretinal,\n                  subretinal, sub-retinal pigment epithelial\n\n        Exclusion Criteria:\n\n          1. Extramacular PCV\n\n          2. Subretinal hemorrhage or other retinal lesions blocking angiographic characteristics\n             in more than 50% area of PCV lesion.\n\n          3. Previous treatment of intravitreal injections (anti-VEGF, steroid or other agents)\n\n          4. Previous treatment of photodynamic therapy\n\n          5. Previous ocular surgery except cataract surgery before 3 or more months\n\n          6. Presence of exudative AMD in the other eyes requiring anti-VEGF treatment\n             (Intravitreal bevacizumab was reported to affect the other eye.)\n\n          7. Presence of other ocular diseases which may affect visual acuity (glaucoma, cataract\n             with opacity involving visual axis, etc)\n\n          8. Presence of uncontrolled systemic disease (diabetes mellitus, hypertension, ischemic\n             heart disease, cerebral infarction, etc)\n\n          9. Patients who cannot understand or conform to the study protocol.\n\n         10. Patients who refuse to agree to the informed consent.\n\n         11. Patients with contraindication to aflibercept\n\n               -  Ocular or periocular infection\n\n               -  Active severe intraocular inflammation\n\n               -  Known hypersensitivity to aflibercept or to any of the excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950741", 
            "org_study_id": "D-1304-013-014"
        }, 
        "intervention": {
            "arm_group_label": "aflibercept", 
            "description": "Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.", 
            "intervention_name": "aflibercept", 
            "intervention_type": "Drug", 
            "other_name": "Eyelea, VEGF Trap-Eye"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "maekbak@hanmail.net", 
                    "last_name": "Hyun Woong Kim, MD, PhD", 
                    "phone": "+82-51-890-8746"
                }, 
                "facility": {
                    "address": {
                        "city": "Busanjin-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Busan", 
                        "zip": "614-735"
                    }, 
                    "name": "Busan Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Hyun Woong Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jooeun2@gmail.com", 
                    "last_name": "Joo-eun Lee, MD, PhD", 
                    "phone": "+82-51-797-2310"
                }, 
                "facility": {
                    "address": {
                        "city": "Haeundae", 
                        "country": "Korea, Republic of", 
                        "state": "Busan", 
                        "zip": "612-030"
                    }, 
                    "name": "Haeundae Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Joo-eun Lee, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jlee@pusan.ac.kr", 
                    "last_name": "Ji Eun Lee, MD, PhD", 
                    "phone": "+82-51-240-7957"
                }, 
                "facility": {
                    "address": {
                        "city": "Seo-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Busan", 
                        "zip": "602-739"
                    }, 
                    "name": "Pusan National University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Ji Eun Lee, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Min Kyu Shin, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sungwho Park, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hhiatus@hanmail.net", 
                    "last_name": "Sangjoon Lee, MD, PhD", 
                    "phone": "+82-10-9335-1487"
                }, 
                "facility": {
                    "address": {
                        "city": "Seo-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Busan", 
                        "zip": "602-702"
                    }, 
                    "name": "Gospel Hospital"
                }, 
                "investigator": {
                    "last_name": "Sangjoon Lee, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jps11@hanmail.net", 
                    "last_name": "Jae Pil Shin, MD, PhD", 
                    "phone": "+82-10-45045801"
                }, 
                "facility": {
                    "address": {
                        "city": "Jung-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Daegu"
                    }, 
                    "name": "Kyungpook National University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Jae Pil Shin, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Dong Ho Park, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "eyedr@dsmc.or.kr", 
                    "last_name": "Yu-Cheol Kim, MD, PhD", 
                    "phone": "+82-53-250-8437"
                }, 
                "facility": {
                    "address": {
                        "city": "Jung-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Daegu"
                    }, 
                    "name": "Keimyung University Dongsan Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Yu-Cheol Kim, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kwang Soo Kim, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "changwh@ynu.ac.kr", 
                    "last_name": "Woohyok Chang, MD, PhD", 
                    "phone": "+82-53-620-3443"
                }, 
                "facility": {
                    "address": {
                        "city": "Nam-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Daegu", 
                        "zip": "705-717"
                    }, 
                    "name": "Yeungnam University Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Woohyok Chang, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Min Sagong, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "in0chung@hanmail.net", 
                    "last_name": "Inyoung Chung, MD, PhD", 
                    "phone": "+82-55-750-8728"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinju", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeongsangnam-do", 
                        "zip": "660-702"
                    }, 
                    "name": "Gyeongsang National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Inyoung Chung, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy", 
        "overall_contact": {
            "email": "jlee@pusan.ac.kr", 
            "last_name": "Ji Eun Lee, MD, PhD", 
            "phone": "+82-51-240-7957"
        }, 
        "overall_official": {
            "affiliation": "Kyungbuk National University Hospital", 
            "last_name": "Jae Pil Shin, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients lose visual acuity less than 3 lines or 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters", 
            "measure": "Visual acuity reservation", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "reference": [
            {
                "PMID": "17021319", 
                "citation": "Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44."
            }, 
            {
                "PMID": "17021318", 
                "citation": "Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31."
            }, 
            {
                "PMID": "23084240", 
                "citation": "Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10."
            }, 
            {
                "PMID": "20719300", 
                "citation": "Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol. 2010 Nov;150(5):666-73. doi: 10.1016/j.ajo.2010.05.035. Epub 2010 Aug 16."
            }, 
            {
                "PMID": "22426346", 
                "citation": "Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453-64."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950741"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pusan National University Hospital", 
            "investigator_full_name": "Ji Eun Lee", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean changes of visual acuity in ETDRS letters", 
                "measure": "Visual acuity changes", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Proportion of patients  having  visual acuity more than 20/200", 
                "measure": "Visual acuity >20/200", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Proportion of patients having visual acuity more than 20/40", 
                "measure": "Visual acuity >20/40", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Proportion of patients having complete resolution  of polypoidal lesion in ICG angiography", 
                "measure": "ICG angiography", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "VFQ (visual function questionaire)-25 score", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Pusan National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pusan National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}